Advertisement

Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5: is it significant?

  • Ravindra Attur PrabhuEmail author
  • Aswani Srinivas Mareddy
  • Shankar Prasad Nagaraju
  • Dharshan Rangaswamy
  • Vasudeva Guddattu
Nephrology - Original Paper
  • 1 Downloads

Abstract

Purpose

To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5.

Methods

We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug.

Result

Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4.

Conclusion

Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.

Keywords

Chronic kidney disease Lactic acidosis Metformin Type 2 diabetes mellitus 

Notes

Acknowledgements

This study was funded through a seed grant from Manipal Academy of Higher Education, India.

Author contribution

RAP: study concept and design, ASM: acquisition of data, SPN and DR: preparation of manuscript, VG: statistical analysis. All authors contributed to the preparation of the report and approved the final version. We have included a conflict of interest disclosure statement in the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Statement of ethics

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Powers AC, Niswender KD, Rickels MR. Diabetes Mellitus: Management and Therapies. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (eds) Harrison’s Principles of Internal Medicine, 20e New York, NY: McGraw-Hill. http://accessmedicine.mhmedical.com.kmcezproxy.manipal.edu/content.aspx?Bookid=2129&sectionid=192288412. Accessed 01 Nov 2018
  2. 2.
    Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with Type 2 diabetes and kidney disease: a systematic review. JAMA 312(24):2668–2675.  https://doi.org/10.1001/jama.2014.15298 CrossRefGoogle Scholar
  3. 3.
    Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M (2002) Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Int Med 13(7):428.  https://doi.org/10.1016/S0953-6205(02)00131-0 CrossRefGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention. Chronic kidney disease surveillance system—United States. Website. http://www.cdc.gov/ckd. Accessed 6 Nov 2018
  5. 5.
    Lazarus B, Wu A, Shin J et al (2018) Association of Metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Int Med 178(7):903–910.  https://doi.org/10.1001/jamainternmed.2018.02925 CrossRefGoogle Scholar
  6. 6.
    Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd002967.pub4 Google Scholar
  7. 7.
    Yeh HC, Ting IW, Tsai CW, Wu JY, Kuo CC (2017) Serum lactate level and mortality in metformin-associated lactic acidosis requiring renal replacement therapy: a systematic review of case reports and case series. BMC Nephrol 18(1):229CrossRefGoogle Scholar
  8. 8.
    van Berlo‐van de Laar IR, Vermeij CG, Doorenbos CJ (2011) Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. Journal of clinical pharmacy and therapeutics 36(3):376–382CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of NephrologyKasturba Medical College and Hospital Manipal, Manipal Academy Higher EducationUdupiIndia
  2. 2.Department of StatisticsPrasanna School of Public Health, MAHEUdupiIndia

Personalised recommendations